Barclays PLC raised its stake in shares of Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) by 699.2% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 473,077 shares of the medical equipment provider’s stock after acquiring an additional 413,885 shares during the period. Barclays PLC owned approximately 0.23% of Corindus Vascular Robotics worth $2,025,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Cambridge Investment Research Advisors Inc. acquired a new position in Corindus Vascular Robotics during the 3rd quarter worth approximately $39,000. Steward Partners Investment Advisory LLC grew its holdings in Corindus Vascular Robotics by 36.4% during the second quarter. Steward Partners Investment Advisory LLC now owns 15,000 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 4,000 shares during the period. Merit Financial Group LLC purchased a new position in Corindus Vascular Robotics in the third quarter worth $44,000. Tealwood Asset Management Inc. raised its position in Corindus Vascular Robotics by 50.0% in the second quarter. Tealwood Asset Management Inc. now owns 15,000 shares of the medical equipment provider’s stock worth $45,000 after acquiring an additional 5,000 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. acquired a new stake in Corindus Vascular Robotics in the second quarter valued at $58,000.
Shares of CVRS opened at $4.27 on Friday. Corindus Vascular Robotics Inc has a twelve month low of $0.78 and a twelve month high of $4.40.
CVRS has been the topic of several research analyst reports. Zacks Investment Research lowered shares of Corindus Vascular Robotics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 13th. Cowen downgraded shares of Corindus Vascular Robotics from an “outperform” rating to a “market perform” rating and increased their price target for the company from $4.00 to $4.28 in a report on Thursday, August 8th.
Corindus Vascular Robotics Company Profile
Corindus Vascular Robotics, Inc designs, manufactures, and sells robotic-assisted systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath system, a medical device with robotic-assisted precision for coronary and peripheral interventional procedures.
See Also: QQQ ETF
Want to see what other hedge funds are holding CVRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS).
Receive News & Ratings for Corindus Vascular Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics and related companies with MarketBeat.com's FREE daily email newsletter.